Synta Pharmaceuticals (SNTA) To Present On Hsp90-inhibitor Drug Conjugate Platform At The 12th International Congress On Targeted Anticancer Therapies
3/3/2014 7:15:39 AM
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the following late-breaking poster presentation will be made at the 12th International Congress on Targeted Anticancer Therapies in Washington, D.C.:
“Hsp90 Inhibitor Drug Conjugates (HDCs): A Novel Drug Delivery Platform Technology”
Help employers find you! Check out all the jobs and post your resume.
comments powered by